¼¼°èÀÇ ÀÓ»ó½ÃÇè ¹ÙÀÌ¿À¸®Æ÷ÁöÅ丮 ¹× ¾ÆÄ«ÀÌºê ¼Ö·ç¼Ç ½ÃÀå
Clinical Trial Biorepository and Archiving Solutions
»óǰÄÚµå : 1779789
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 377 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,204,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,612,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ÀÓ»ó½ÃÇè ¹ÙÀÌ¿À¸®Æ÷ÁöÅ丮 ¹× ¾ÆÄ«ÀÌºê ¼Ö·ç¼Ç ½ÃÀåÀº 2030³â±îÁö 63¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 42¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ÀÓ»ó½ÃÇè ¹ÙÀÌ¿À¸®Æ÷ÁöÅ丮 ¹× ¾ÆÄ«ÀÌºê ¼Ö·ç¼Ç ½ÃÀåÀº 2024-2030³â¿¡ CAGR 6.7%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 63¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ¹ÙÀÌ¿À¸®Æ÷ÁöÅ丮 ¼­ºñ½º´Â CAGR 8.0%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 39¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾ÆÄ«ÀÌºê ¼Ö·ç¼Ç ¼­ºñ½º ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 4.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 12¾ï ´Þ·¯, Áß±¹Àº CAGR 10.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ ÀÓ»ó½ÃÇè ¹ÙÀÌ¿À¸®Æ÷ÁöÅ丮 ¹× ¾ÆÄ«ÀÌºê ¼Ö·ç¼Ç ½ÃÀåÀº 2024³â¿¡ 12¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 13¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 10.8%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 3.2%¿Í 6.6%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.4%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÀÓ»ó½ÃÇè ¹ÙÀÌ¿À¸®Æ÷ÁöÅ丮 ¹× ¾ÆÄ«ÀÌºê ¼Ö·ç¼Ç ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÀÓ»ó½ÃÇè¿¡ ¹ÙÀÌ¿À¸®Æ÷ÁöÅ丮°¡ ÇʼöÀûÀÎ ÀÌÀ¯

¹ÙÀÌ¿À¸®Æ÷ÁöÅ丮´Â Ç÷¾×, Á¶Á÷, DNA, RNA »ùÇÃÀ» Æ÷ÇÔÇÑ »ý¹°ÇÐÀû ½Ã·áÀÇ ¾ÈÀüÇÑ º¸°ü ¹× °ü¸®¸¦ Á¦°øÇÔÀ¸·Î½á ÀÓ»ó½ÃÇè¿¡¼­ ±âº»ÀûÀÎ ¿ªÇÒÀ» ¼öÇàÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ½Ã¼³Àº »ý¹°ÇÐÀû ½Ã·áÀÇ ¹«°á¼ºÀ» º¸ÀåÇϰí, ¿¬±¸ÀÚµéÀÌ ÀǾàǰ °³¹ß, ¸ÂÃãÀÇ·á, ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö¿¡ ÀÖÀ¸¸ç, °íǰÁúÀÇ ÀçÇö¼º ÀÖ´Â ¿¬±¸¸¦ ¼öÇàÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù. ƯÈ÷ Á¾¾çÇÐ, ¸é¿ªÇÐ, Èñ±ÍÁúȯ ºÐ¾ßÀÇ ÀÓ»ó½ÃÇèÀÌ º¹ÀâÇØÁü¿¡ µû¶ó ÷´Ü ¹ÙÀÌ¿À¹ðÅ© ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ³Ãµ¿º¸Á¸±â¼ú°ú ÃÊÀú¿Âº¸Á¸±â¼úÀº Àå±âÀûÀ¸·Î »ý¹° ½Ã·áÀÇ »ýÁ¸¼ºÀ» À¯ÁöÇϰí, ÇâÈÄ ¿¬±¸¿¡ Ȱ¿ë °¡´É¼ºÀ» È®º¸ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¶ÇÇÑ ½Ã·á ¼öÁý, ó¸®, µ¥ÀÌÅÍ °ü¸®¸¦ À§ÇÑ Ç¥ÁØÈ­µÈ ÇÁ·ÎÅäÄÝÀº ÀúÀåµÈ ½Ã·áÀÇ ½Å·Ú¼ºÀ» ³ôÀ̰í, ÀÓ»ó ¿¬±¸ °á°úÀÇ ÆíÂ÷¸¦ ÁÙÀÔ´Ï´Ù. Á¤¹ÐÀÇ·á·ÎÀÇ Àüȯ°ú ÇÔ²² ¹ÙÀÌ¿À¸®Æ÷ÁöÅ丮´Â À¯ÀüÀÚ, ÇÁ·ÎÅ׿È, ¸ÞŸº¼·Ò µ¥ÀÌÅÍ¿Í ÀÓ»ó Ç¥ÇöÇüÀ» ¿¬°áÇÏ¿© Áúº´ ±âÀü ¹× Ä¡·á ¹ÝÀÀ¿¡ ´ëÇÑ ´õ ±íÀº ÀλçÀÌÆ®¸¦ ÃËÁøÇÏ´Â µ¥ ÇʼöÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

¹ÙÀÌ¿À¸®Æ÷ÁöÅ丮 ±â¼úÀÇ ¹ßÀüÀ̶õ?

¹ÙÀÌ¿À¸®Æ÷ÁöÅ丮 ±â¼úÀÇ Çõ½ÅÀº ½Ã·áÀÇ º¸Á¸¼º, Á¢±Ù¼º, µ¥ÀÌÅÍ ¹«°á¼ºÀ» Å©°Ô Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÀÚµ¿È­µÈ º¸°ü ¹× °Ë»ö ½Ã½ºÅÛÀº ½Ã·á °ü¸®ÀÇ È¿À²¼ºÀ» Çâ»ó½Ã۰í, ÀÎÀ§ÀûÀÎ ½Ç¼ö³ª ½Ã·á º¯ÁúÀÇ À§ÇèÀ» ÃÖ¼ÒÈ­ÇÕ´Ï´Ù. AI ±â¹Ý ¹ÙÀÌ¿À¹ðÅ© ¼ÒÇÁÆ®¿þ¾î´Â »ýü ½Ã·áÀÇ ½Ç½Ã°£ ÃßÀûÀÌ °¡´ÉÇϸç, ±ÔÁ¦ °¡À̵å¶óÀΰú ¿¬±¸ ÇÁ·ÎÅäÄÝÀ» ÁؼöÇÒ ¼ö ÀÖµµ·Ï º¸ÀåÇÕ´Ï´Ù. ½Ã·á ÃßÀû¼º¿¡¼­ ºí·ÏüÀÎ ±â¼úÀÇ ÅëÇÕÀº »ý¹°ÇÐÀû ½Ã·á º¸°ü ¾÷¹«ÀÇ º¸¾È°ú Åõ¸í¼ºÀ» °­È­Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¾×ü»ý°Ë º¸Á¸ ¼Ö·ç¼ÇÀÇ ¹ßÀüÀ¸·Î ¼øÈ¯ Á¾¾ç DNA(ctDNA) ¹× ±âŸ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ Àå±â º¸Á¸ÀÌ °¡´ÉÇØÁ® ÁøÇà ÁßÀÎ ¾Ï ¿¬±¸¸¦ Áö¿øÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. Ŭ¶ó¿ìµå ±â¹Ý ¹ÙÀÌ¿À¸®Æ÷ÁöÅ丮 °ü¸® ½Ã½ºÅÛÀº Àü ¼¼°è ¿¬±¸±â°ü °£ÀÇ ¿øÈ°ÇÑ Çù¾÷À» ÃËÁøÇÏ°í ´Ù±â°ü ÀÓ»ó½ÃÇè¿¡¼­ Áß¿äÇÑ »ý¹°ÇÐÀû µ¥ÀÌÅ͸¦ °øÀ¯ÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù. ÀÓ»ó ¿¬±¸ÀÇ ±Ô¸ð¿Í ¹üÀ§°¡ °è¼Ó È®´ëµÊ¿¡ µû¶ó Â÷¼¼´ë ¹ÙÀÌ¿À¸®Æ÷ÁöÅ丮´Â ½Å¾à°³¹ß°ú Ä¡·á Çõ½ÅÀ» °¡¼ÓÈ­ÇÏ´Â µ¥ ÀÖÀ¸¸ç, Á¡Á¡ ´õ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

ÀÓ»ó½ÃÇè ¹ÙÀÌ¿À¸®Æ÷ÁöÅ丮 ½ÃÀåÀº ¾î¶»°Ô ÁøÈ­Çϰí Àִ°¡?

ÀÓ»ó½ÃÇèÀÇ º¹À⼺ÀÌ Áõ°¡ÇÏ°í ±ÔÁ¦ ¿ä°ÇÀÌ °­È­µÊ¿¡ µû¶ó ¹ÙÀÌ¿À¸®Æ÷ÁöÅ丮 ¹× ¾ÆÄ«ÀÌºê ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇè ¼öʱâ°ü(CRO)°ú Á¦¾à»çµéÀº ´ë±Ô¸ð ÀÓ»ó½ÃÇèÀ» Áö¿øÇÏ°í ½Ã·áÀÇ ¹«°á¼ºÀ» º¸ÀåÇϱâ À§ÇØ ÃÖ÷´Ü ¹ÙÀÌ¿À¹ðÅ© ½Ã¼³¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ºÐ»êÇü ÀÓ»ó½ÃÇè(DCT)ÀÇ ÃâÇöÀº ¿ø°Ý »ýü ½Ã·á ¼öÁý ¹× µðÁöÅÐ ½Ã·á ÃßÀû ¼Ö·ç¼ÇÀÇ Çʿ伺À» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ GDPR(EU °³ÀÎÁ¤º¸º¸È£±ÔÁ¤), HIPAA µîÀÇ À±¸®Àû °í·Á»çÇ×°ú µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã ±ÔÁ¦°¡ ÀÎüÀ¯·¡¹° º¸°ü½Ã¼³ÀÇ °Å¹ö³Í½º¸¦ Çü¼ºÇϰí ÀÖÀ¸¸ç, ¾ÈÀüÇϰí ÄÄÇöóÀ̾𽺸¦ ÁؼöÇÏ´Â ÀÎüÀ¯·¡¹° º¸°ü½Ã¼³ ÀÎÇÁ¶óÀÇ Çʿ伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù. Áö¼Ó°¡´É¼º Ãß¼¼´Â ÀÎüÀ¯·¡¹° º¸°ü½Ã¼³ ¿î¿µ¿¡µµ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, ¿¬±¸½Ã¼³Àº ¿¡³ÊÁö È¿À²ÀÌ ³ôÀº º¸°ü½Ã½ºÅÛ°ú ģȯ°æ ³Ãµ¿º¸Á¸ ±â¼úÀ» äÅÃÇϰí ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇ·á¿Í Áß°³¿¬±¸¿¡¼­ ¹ÙÀÌ¿À¹ðÅ© ½Ã·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¹ÙÀÌ¿À¹ðÅ©´Â µ¥ÀÌÅͺ£À̽ºÀÇ ÀÓ»ó Çõ½ÅÀ» À§ÇÑ ¿ªµ¿ÀûÀÎ Çãºê·Î ÁøÈ­Çϰí ÀÖ½À´Ï´Ù.

ÀÓ»ó½ÃÇè ¹ÙÀÌ¿À¸®Æ÷ÁöÅ丮 ½ÃÀåÀÇ ¼ºÀå µ¿·ÂÀº?

ÀÓ»ó½ÃÇè ¹ÙÀÌ¿À¸®Æ÷ÁöÅ丮 ¹× ¾ÆÄ«ÀÌºê ¼Ö·ç¼Ç ½ÃÀåÀÇ ¼ºÀåÀº Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, ¹ÙÀÌ¿À¸¶Ä¿ Áß½ÉÀÇ ¿¬±¸°³¹ß Áõ°¡, ¼¼°è Àӻ󿬱¸ ±¸»óÀÇ È®´ë µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. À¯ÀüüÇÐ, ´Ü¹éÁúüÇÐ, ´ë»çüÇÐ ¿¬±¸ÀÇ È®´ë·Î °íǰÁú »ý¹° ½Ã·á¿¡ ´ëÇÑ ¼ö¿ä°¡ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ³Ãµ¿º¸Á¸ ¹× ÀÚµ¿ ¹ÙÀÌ¿À¹ðÅ© ½Ã½ºÅÛÀÇ ±â¼úÀû ¹ßÀüÀº »ý¹° ½Ã·áÀÇ º¸Á¸ È¿À²¼º°ú ½Å·Ú¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù. »ý¹° ½Ã·á º¸°ü ½Ã¼³ ¿î¿µ¿¡ ¾ö°ÝÇÑ Ç°Áú°ü¸®¿Í À±¸®Àû °¡À̵å¶óÀÎÀ» Àǹ«È­ÇÏ´Â ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©°¡ ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½Ã·á ÃßÀû ¹× ¸ÞŸµ¥ÀÌÅÍ ºÐ¼®¿¡¼­ ÀΰøÁö´É¿¡ ´ëÇÑ ÀÇÁ¸µµ°¡ ³ô¾ÆÁü¿¡ µû¶ó º¸°üµÈ ½Ã·áÀÇ °ü¸®°¡ ÃÖÀûÈ­µÇ°í ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á Á¢±Ù¹ýÀÇ È®»êÀº ÃæºÐÈ÷ Ư¼ºÈ­µÈ ÀÎüÀ¯·¡¹° º¸°ü½Ã¼³ÀÇ Çʿ伺À» °­È­Çϰí ÀÖÀ¸¸ç, ¹ÙÀÌ¿À¹ðÅ© ÀÎÇÁ¶ó¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ÅõÀÚ¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇè ¼³°è°¡ º¹ÀâÇØÁü¿¡ µû¶ó ½Å¾à °³¹ß ¹× ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ» °¡¼ÓÈ­ÇÏ´Â ¹ÙÀÌ¿À¸®Æ÷ÁöÅ丮ÀÇ ¿ªÇÒÀº °è¼Ó È®´ëµÉ °ÍÀ̸ç, ½ÃÀåÀº Àå±âÀûÀÎ ¼ºÀåÀ» ÀÌ·ê °ÍÀÔ´Ï´Ù.

ºÎ¹®

¼­ºñ½º À¯Çü(¹ÙÀÌ¿À¸®Æ÷ÁöÅ丮, ¾ÆÄ«ÀÌºê ¼Ö·ç¼Ç), Á¦Ç° À¯Çü(ÀüÀÓ»ó, ÀÓ»ó), ´Ü°è À¯Çü(ÀüÀÓ»ó, ´Ü°è I, ´Ü°è II, ´Ü°è III, ´Ü°è IV)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À Æ®·£½º Ŭ¸³Æ®, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è µµ¸ÞÀÎ Àü¹®°¡·ÎºÎÅÍ Å¥·¹ÀÌÆ®µÈ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Clinical Trial Biorepository and Archiving Solutions Market to Reach US$6.3 Billion by 2030

The global market for Clinical Trial Biorepository and Archiving Solutions estimated at US$4.2 Billion in the year 2024, is expected to reach US$6.3 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. Biorepository Services, one of the segments analyzed in the report, is expected to record a 8.0% CAGR and reach US$3.9 Billion by the end of the analysis period. Growth in the Archiving Solution Services segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 10.8% CAGR

The Clinical Trial Biorepository and Archiving Solutions market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 10.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Clinical Trial Biorepository and Archiving Solutions Market - Key Trends & Drivers Summarized

Why Are Biorepositories Essential for Clinical Trials?

Biorepositories play a fundamental role in clinical trials by providing secure storage and management of biological specimens, including blood, tissue, DNA, and RNA samples. These facilities ensure the integrity of biospecimens, enabling researchers to conduct high-quality, reproducible studies in drug development, personalized medicine, and biomarker discovery. The growing complexity of clinical trials, particularly in oncology, immunology, and rare diseases, has intensified the demand for advanced biobanking solutions. Cryopreservation and ultra-low temperature storage technologies are critical in maintaining the viability of biospecimens over extended periods, ensuring their usability for future research. Moreover, standardized protocols for sample collection, processing, and data management are enhancing the reliability of stored specimens, reducing variability in clinical research outcomes. With the shift toward precision medicine, biorepositories are becoming indispensable in linking genetic, proteomic, and metabolomic data to clinical phenotypes, facilitating deeper insights into disease mechanisms and treatment responses.

What Are the Advancements in Biorepository Technologies?

Innovations in biorepository technologies are significantly enhancing sample preservation, accessibility, and data integrity. Automated storage and retrieval systems are improving the efficiency of specimen management, minimizing the risk of human error and sample degradation. AI-powered biobanking software is enabling real-time tracking of biospecimens, ensuring compliance with regulatory guidelines and study protocols. The integration of blockchain technology in sample traceability is enhancing security and transparency in biorepository operations. Additionally, advancements in liquid biopsy storage solutions are allowing for the long-term preservation of circulating tumor DNA (ctDNA) and other biomarkers, supporting ongoing cancer research. Cloud-based biorepository management systems are facilitating seamless collaboration among global research institutions, enabling multi-center clinical trials to share critical biological data. As the scale and scope of clinical research continue to expand, next-generation biorepositories are playing an increasingly vital role in accelerating drug discovery and therapeutic innovation.

How Is the Market for Clinical Trial Biorepositories Evolving?

The demand for biorepository and archiving solutions is growing as clinical trial complexity increases and regulatory requirements become more stringent. Contract research organizations (CROs) and pharmaceutical companies are investing in state-of-the-art biobanking facilities to support large-scale trials and ensure sample integrity. The emergence of decentralized clinical trials (DCTs) is driving the need for remote biospecimen collection and digital sample tracking solutions. Moreover, ethical considerations and data privacy regulations, such as GDPR and HIPAA, are shaping the governance of biospecimen storage, emphasizing the need for secure and compliant biorepository infrastructure. Sustainability trends are also influencing biorepository operations, with laboratories adopting energy-efficient storage systems and eco-friendly cryopreservation technologies. As the demand for biobanked specimens rises in precision medicine and translational research, biorepositories are evolving into dynamic hubs for data-driven clinical innovation.

What’s Driving the Growth of the Clinical Trial Biorepository Market?

The growth in the clinical trial biorepository and archiving solutions market is driven by several factors, including increasing investments in precision medicine, the rise of biomarker-driven drug development, and expanding global clinical research initiatives. The demand for high-quality biospecimens is accelerating, fueled by the expansion of genomics, proteomics, and metabolomics research. Technological advancements in cryopreservation and automated biobanking systems are enhancing the efficiency and reliability of biospecimen storage. Regulatory frameworks mandating strict quality control and ethical guidelines for biorepository operations are further propelling market growth. Additionally, the increasing reliance on artificial intelligence for sample tracking and metadata analysis is optimizing the management of stored specimens. The proliferation of personalized medicine approaches is intensifying the need for well-characterized biospecimen repositories, driving sustained investments in biobanking infrastructure. As clinical trial designs become more complex, the role of biorepositories in accelerating drug discovery and regulatory approvals continues to expand, positioning the market for long-term growth.

SCOPE OF STUDY:

The report analyzes the Clinical Trial Biorepository and Archiving Solutions market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Service Type (Biorepository Services, Archiving Solution Services); Product Type (Preclinical Products, Clinical Products); Phase Type (Preclinical, Phase I, Phase II, Phase III, Phase IV)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â